BioSpring and Phenion receive BMBF-Funding for the development of a bioactive for skin treatment
The Frankfurt-based Biotech companies BioSpring GmbH and Phenion GmbH & Co. KG receive public funding of approximately 1 million Euro within the "BioChancePlus" funding program of the German Federal Ministry of education and Research (BMBF). The objective of the common research project is the development of nucleic acid derivatives (oligonucleotides) as topical bioactives for skin calming and treatment of inflamed skin.
During the project oligonucleotide molecules will be synthesized and characterized regarding to their biological activity in the skin within the Phenion®-Full Thickness Skin Model. For further development of suitable oligonucleotides the companies will search a strategic partnership e.g. with the pharmaceutical industry.
Most read news
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Merck Advances to Eighth Place in the 2012 Access to Medicine Index
Evonik achieves major biotech breakthrough with a new animal-free and fermentation-based collagen platform - Recombinant collagen mimics attributes of human collagen

Bacteria Free Themselves with Molecular “Speargun”

Paper-based device developed for rapid diagnosis of lung diseases - CSIC researchers have coordinated the design of an instrument that combines paper microfluidics and electrochemical transduction.
SciGene Moves to Larger Manufacturing and Research Space
Complex production and sales processes weaken a company's competitiveness - Engineering, chemicals and pharmaceuticals need to catch up
Innogenetics extends its diagnostics product portfolio for Alzheimer's disease with new products

Next generation of viral vectors, called AAV 3.0, for gene therapies and genome editing
AmpliPhi and Special Phage Services complete merger
